48 results
424B5
MREO
Mereo Biopharma Group Plc
14 Jun 24
Prospectus supplement for primary offering
4:15pm
in the future;
actions by institutional shareholders;
speculation in the press or the investment community; or
other events and factors, many
DEF 14A
MREO
Mereo Biopharma Group Plc
24 Apr 24
Definitive proxy
7:30am
indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
, adoption by the medical community of our product candidates, if approved, may be limited if third-party payors offer inadequate reimbursement … of our current product candidates by patients, the medical community, and third-party payors; our ability to compete with other therapies to treat OI
10-K
2023 FY
EX-19.1
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
of the investment community;
The potential or actual gain or loss of a significant customer, supplier, or purchase order;
Joint ventures and distribution
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
17 Oct 23
Current report (foreign)
7:01am
want to acknowledge the OI community and especially thank the people living with OI and their caregivers who have aided the setrusumab development
6-K
EX-99.2
t0jcus6bu67o7lrco0
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.2
z04jmbox
2 Nov 22
Current report (foreign)
4:17pm
6-K
EX-99.1
t4fngs29nz
26 May 22
Current report (foreign)
5:11pm
6-K
EX-99.2
g5v brlmig
2 Nov 21
Current report (foreign)
4:16pm
F-3
EX-4.4
z83l3q
5 Aug 21
Shelf registration (foreign)
4:33pm
424B5
u76k4i5hovrw
10 Feb 21
Prospectus supplement for primary offering
4:53pm
424B5
smw3h212 5fix6yu8
9 Feb 21
Prospectus supplement for primary offering
5:24pm
6-K
EX-99.1
d6bx lpj59qv
17 Dec 20
Mereo BioPharma and Ultragenyx Announce Collaboration and License
5:16pm
424B5
pzi9vpe
23 Oct 20
Prospectus supplement for primary offering
4:40pm